Hydrogel could be potential treatment for metabolic dysfunction-associated steatotic liver disease

Coverage, in order

1. 8d ago
   
   Medical Xpress indie

   Hydrogel could be potential treatment for metabolic dysfunction-associated steatotic liver disease

   Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 38% of the global population, with prevalence continuing to rise in parallel with the global burden of metabolic syndrome. Although several pharmacological agents are currently under clinical investigation…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.